Earnings

Five things for pharma marketers to know: Monday, November 13, 2017

Five things for pharma marketers to know: Monday, November 13, 2017

By

Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head

Five things for pharma marketers to know: Thursday, November 2, 2017

Five things for pharma marketers to know: Thursday, November 2, 2017

By

Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III

Analysts agree with WPP that threat from consultancies has been 'overhyped'

Analysts agree with WPP that threat from consultancies has been 'overhyped'

By

During its third quarter earnings call yesterday, WPP dismissed the threat from management consultants as "overhyped". Analysts concur.

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Thursday, October 26, 2017

Five things for pharma marketers to know: Thursday, October 26, 2017

By

Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug

Five things for pharma marketers to know: Wednesday, October 25, 2017

Five things for pharma marketers to know: Wednesday, October 25, 2017

By

FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs

Five things for pharma marketers to know: Tuesday, October 17, 2017

Five things for pharma marketers to know: Tuesday, October 17, 2017

By

J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing

Omnicom continues organic growth lead over rival ad networks

Omnicom continues organic growth lead over rival ad networks

By

By comparison, Omnicom's client roster includes less consumer goods companies compared to rivals WPP and Publicis Groupe.

Media is where agencies are hurting

Media is where agencies are hurting

By

Why is revenue growth at some of the agency groups lagging forecasts for global ad expenditure?

Analysts on WPP: 'expected bad, got worse'

Analysts on WPP: 'expected bad, got worse'

By

Business analysts have generally agreed that WPP's half-year earnings fell below expectations given recent market commentary, but have offered mixed guidance going forward.

Five things for pharma marketers to know: Monday, July 31, 2017

Five things for pharma marketers to know: Monday, July 31, 2017

By

FDA launches digital health pre-certification pilot; J&J's experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi

Five things for pharma marketers to know: Thursday, July 27, 2017

Five things for pharma marketers to know: Thursday, July 27, 2017

By

Generic drugmakers reportedly seeking deals; GSK to refocus R&D; Merck and AstraZeneca to test combo cancer drug

Five things for pharma marketers to know: Tuesday, July 25, 2017

Five things for pharma marketers to know: Tuesday, July 25, 2017

By

Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review

Five things for pharma marketers to know: Tuesday, July 18, 2017

Five things for pharma marketers to know: Tuesday, July 18, 2017

By

Novartis raises Alcon forecast; UDG acquires Cambridge BioMarketing; Spark Therapeutics receives priority review for Luxturna gene therapy

Five things for pharma marketers to know: Wednesday, April 26, 2017

Five things for pharma marketers to know: Wednesday, April 26, 2017

By

GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products

J&J blames lower Xarelto and Invokana sales on payer pressure

J&J blames lower Xarelto and Invokana sales on payer pressure

By

The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

By

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Five things for pharma marketers to know: Monday, February 13, 2016

Five things for pharma marketers to know: Monday, February 13, 2016

By

Sanofi to sell five OTC drugs to Ipsen; Teva reports 33% revenue growth in Q4; Regeneron issued subpoena about support of nonprofits

J2 Global considers divesting parts of Everyday Health

J2 Global considers divesting parts of Everyday Health

By

The company acquired Everyday Health in December.

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Five things for pharma marketers to know: Monday, February 6, 2017

Five things for pharma marketers to know: Monday, February 6, 2017

By

Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year

Five things for pharma marketers to know: Thursday, February 2, 2017

Five things for pharma marketers to know: Thursday, February 2, 2017

By

Biogen completes hemophilia spinoff; old drug being tested as a prostate cancer treatment; Merck reports Q4 decline in revenue

Five things for pharma marketers to know: Wednesday, January 25, 2017

Five things for pharma marketers to know: Wednesday, January 25, 2017

By

Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims

Five things for pharma marketers to know: Tuesday, January 24, 2017

Five things for pharma marketers to know: Tuesday, January 24, 2017

By

Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role

Five things for pharma marketers to know: Thursday, November 10, 2016

Five things for pharma marketers to know: Thursday, November 10, 2016

By

Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions

Five things for pharma marketers to know: Tuesday, November 8, 2016

Five things for pharma marketers to know: Tuesday, November 8, 2016

By

FDA solicits public comment to study online character space limit; Biogen's Spinraza shows positive results in SMA study; Valeant cuts earnings forecast

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

By

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Five things for pharma marketers to know: Friday, July 29, 2016

Five things for pharma marketers to know: Friday, July 29, 2016

By

England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

By

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin